EDCTP [to 24 March 2018]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
23 March 2018
World TB Day: EDCTP commits EUR 34M to TB vaccine clinical trials
True to the World Tuberculosis Day 2018 theme ‘Wanted: Leaders for a TB-free world’, the European Union and European member states continue to take an important role in fighting this disease. Recently, the European & Developing Countries Clinical Trials Partnership (EDCTP) committed EUR 34 million in funding for four large clinical trials on candidate TB vaccines. This is the largest European investment into clinical development of TB vaccines to date (with two grants signed and two under preparation), and boosts the joint commitment to combat one of the world’s most devastating diseases. The trials will be conducted by 28 research institutions from sub-Saharan Africa, Europe and India…
22 March 2018
TB treatment consortium PanACEA2 held second annual meeting
The EDCTP-funded PanACEA2 consortium held its second annual meeting in Cape Town, South Africa from 28 February to 1 March 2018. Over the next five years, the consortium plans to use novel trial designs to accelerate the development of new anti-tuberculosis drug regimens. Three clinical trials will be conducted to optimise existing drugs and evaluate novel agents, with the aim of testing combination regimens that will shorten and simplify TB treatment. EDCTP Senior Project Officer Dr Monique Rijks-Surette participated in the programme…
Emory Vaccine Center [to 24 March 2018]
EVC Faculty Win Paper of the Year by International Society for Vaccines
European Medicines Agency [to 24 March 2018]
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 March 2018
Six medicines recommended for approval, including one orphan …
European Vaccine Initiative [to 24 March 2018]
21 March 2018
Recommendations on the design of multi-centre validation studies
Findings from a workshop organised within the VAC2VAC project (Vaccine batch to vaccine batch comparison by consistency testing) on the improved design of multi-centre validation studies and the use the data generated for product-specific validation purposes have now been published (Halder et al, 2018). The recommendations also address aspects of validation within the consistency approach context.
Fondation Merieux [to 24 March 2018]
March 14, 2018 Bamako, Mali
6th Better Foods for Better Health Symposium
The Mérieux Foundation is organizing the 6th edition of the Better Foods for Better Health symposium from March 20-22, at Les Pensières Center for Global Health, Veyrier-du-Lac, in France, with the support of Mérieux NutriSciences. This edition gathers about 100 experts from the scientific community, regulatory institutions, academia, agro-food and industry stakeholders to discuss “Childhood nutrition, building a healthy life”.’’
Gavi [to 24 March 2018]
23 March 2018
U.S. approves $290 million for Gavi in fiscal year 2018 appropriations omnibus
Funding to provide critical vaccines to some of the poorest children in the world.
Washington, 23 March 2018 – Gavi, the Vaccine Alliance welcomed final approval of the United States fiscal year 2018 appropriations bill. The budget includes US$ 290 million for Gavi, which will go towards increasing the organization’s capacity to purchase and deliver life-saving vaccines for poor and vulnerable children around the world.
The contribution to Gavi is part of the US$ 829.5 million approved for the U.S. Agency for International Development (USAID) Maternal and Child Health programs for 2018. This funding not only supports the introduction of new vaccines and innovative approaches and tools to expand equitable access to vaccines, but a range of other life-saving interventions.
“Gavi is grateful to the United States for continuing to invest in vaccines, one of the most cost-effective ways to save lives, improve health and ensure long-term prosperity,” said Gavi CEO Dr. Seth Berkley…
Global Fund [to 24 March 2018]
Global Fund Thanks U.S. Congress for Steadfast Support against HIV, TB and Malaria
23 March 2018
The Global Fund applauds the U.S. Congress for approving $1.35 billion in funding for the Global Fund for the 2018 U.S. fiscal year. This tremendous support from the United States is essential as the Global Fund accelerates progress in the fight against AIDS, tuberculosis, and malaria.
The Global Fund also welcomed Congressional appropriation of $4.65 billion for the U.S. President’s Emergency Plan for AIDS Relief, $755 million for the U.S. President’s Malaria Initiative, and $261 million for USAID’s TB program. The Global Fund is a critical partner to all three of these U.S. bilateral efforts.
The sustained U.S. support for the Global Fund will strengthen economic growth and help reduce poverty in Global Fund implementing countries. It will also save lives, reduce suffering, and bolster health security across the globe. The Global Fund matches every dollar from the U.S. with two dollars from other donors to drive global progress.
“The support of the American people is fundamental to global progress in ending the epidemics of HIV, TB, and malaria,” said Peter Sands, Executive Director of the Global Fund. “Together, we will continue to deliver results – in close collaboration with PEPFAR, PMI, and USAID’s TB program – and will accelerate the end of these epidemics.”…
Human Vaccines Project [to 24 March 2018]
Mar 22, 2018
Human Vaccines Project Appoints Dr. Moncef Slaoui as New Board Member
NEW YORK, March 22, 2018 /PRNewswire/ — The Human Vaccines Project, a nonprofit public-private partnership focused on decoding the immune system to improve human health, welcomes Moncef Slaoui, PhD, to its Board of Directors.
Moncef Slaoui, PhD, has had a highly distinguished career in vaccine R&D and has led the development of numerous vaccines that are in use worldwide. In 2016, he was recognized as one of Fortune Magazine’s “50 Greatest World Leaders” for his work on under-researched diseases that are common in the developing world. Dr. Slaoui is currently a partner at Medicxi, a leading European venture capital firm.
“We are honored to have Dr. Slaoui join the Project’s Board of Directors. He brings tremendous expertise in technology development and vaccine research to the table that is specifically relevant to the Project’s mission,” said Wayne C. Koff, PhD, president and CEO of the Human Vaccines Project. “We look forward to his guidance on this next phase of development, as the Project’s clinical research advances our understanding of the immune system.”…
IAVI [to 24 March 2018]
March 20, 2018
IAVI Remembers HIV Treatment Pioneer David Cooper
IAS Past President David Cooper championed breakthrough AIDS treatment and advocated for a vaccine
IAVI is saddened by the passing of David Cooper, MD, DSc, whose breakthrough research and unrelenting advocacy helped usher in the use of life-saving antiretroviral (ARV) therapy and advance efforts to turn the tide of the epidemic. David leaves behind an indelible legacy as a scientist, clinician, and advocate whose contributions over three decades in the fight against AIDS helped enable transformation of the disease from an almost invariably fatal one to one where highly effective, well-tolerated, and simple-to-use treatment regimens are now available.
“David Cooper was an early leader in HIV treatment and prevention, and an inspiration for so many people in the AIDS field, myself included,” said Mark Feinberg, MD, PhD, CEO of IAVI. “David was exceptionally dedicated to the care of individuals living with HIV and so very thoughtful and generous with his colleagues. His passing is a loss not only to our field but to the many people who were encouraged by him in their efforts to combat AIDS.”…
IVAC [to 24 March 2018]
Latest IVAC News
IVAC Launches Immunization Reminder and Information SMS System (IRISS) in Nigeria
MSF/Médecins Sans Frontières [to 24 March 2018]
Syria: Military Operations in Eastern Ghouta Drastically Limit Medical Aid
MARCH 21, 2018—Lorena Bilbao, Syria operations coordinator for Doctors Without Borders/Médecins Sans Frontières (MSF), gave the following statement today on the situation in eastern Ghouta, Syria:
Mediterranean: European Governments Continue to Obstruct Lifesaving Rescues and Return People to Unsafe Conditions in Libya
March 21, 2018
The decision by Italian authorities to seize Open Arms, a rescue vessel belonging to the Spanish NGO Proactiva, shortly after its crew rescued and disembarked 216 people in the Central Mediterranean on Sunday is the latest in a long series of actions obstructing non-governmental organizations from carrying out lifesaving rescue operations at sea, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today.
Greece: Europe’s Two-Year-Old Deal with Turkey Traps Thousands in Disastrous Conditions
ATHENS /NEW YORK, MARCH 17, 2018—Two years after the signing of a deal between the European Union (EU) and Turkey, Europe’s cynical strategy to contain and return people seeking asylum has trapped thousands of vulnerable people in disastrous conditions on Greek islands, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) said today, calling on Greek and EU authorities to increase transfers to the Greek mainland.
NIH [to 24 March 2018]
March 23, 2018
NIH Statement on World Tuberculosis Day 2018
— Statement of Christine F. Sizemore, Ph.D., Richard Hafner, M.D., and Anthony S. Fauci, M.D.
[See Milestones/Perspectives above for full text]
March 22, 2018
NIH scientists say advanced vaccines could limit future outbreaks
— Novel vaccine technologies are critical to improving the public health response to infectious disease threats that continually emerge and re-emerge, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. In a perspective in The Journal of the American Medical Association, the experts highlight innovations that could significantly shorten the typical decades-long vaccine development timeline.
[See Milestones/Perspectives above for full text]
PATH [to 24 March 2018]
Press release | March 23, 2018
Ministry of Health and Internet innovators discuss the exciting potential of Vietnam’s growing social media ecosystem to boost HIV control
Workshop highlights how cutting edge online tools are bringing HIV services and support into the digital age
Hanoi, March 23, 2018—Today, the Vietnam Administration for HIV/AIDS Control (VAAC) and the US Agency for International Development’s (USAID) Healthy Markets project, implemented by PATH, brought together young Vietnamese innovators who are using digital and online technology to increase access to HIV-related information and services for at-risk populations. The forum in Hanoi brought together government leaders, private-sector partners, social media and communications experts, civil society leaders, and social enterprises to discuss how the rise of social media, mobile apps, and online commerce in Vietnam can be leveraged to support Vietnam’s commitment to its 90-90-90 goals to eliminate HIV in Vietnam by 2030…
UNAIDS [to 24 March 2018]
Update 23 March 2018
UNAIDS Special Ambassador receives UNWDPA Leadership Award
The United Nations Women for Peace Association (UNWDPA) has honoured Lorena Castillo de Varela, the First Lady of Panama and UNAIDS Special Ambassador for AIDS in Latin America, with its Leadership Award. The award was made in recognition of her work in the response to HIV and the promotion of human rights and women’s empowerment…
Update 21 March 2018
UNAIDS saddened by the death of pioneering HIV researcher David Cooper
UNAIDS is saddened by the news of the sudden death of David Cooper on 18 March. He was a pioneering HIV researcher, immunologist and professor at Australia’s University of New South Wales and in 1986 became the first Director of the National Centre of HIV Epidemiology and Clinical Research, now known as the Kirby Institute.
Mr Cooper diagnosed the first documented case of HIV in Australia in the mid-1980s, and in 1991 was named Chair of the WHO Global Programme on AIDS’ Committee on Clinical Research and Drug Development.
He was a past President of the International AIDS Society and worked with colleagues to found the HIV Netherlands Australia Thailand Research Collaboration, known as HIV-NAT, in Bangkok, Thailand.
“The world has lost a bold and compassionate leader in the response to HIV,” said Michel Sidibé, UNAIDS Executive Director. “David Cooper firmly believed in health as a fundamental human right. Without the groundbreaking research and advances in treatment that he helped to make a reality, many more lives would have been lost to AIDS. Our thoughts during this difficult time are with his family, colleagues and the many people his life and work touched.”…
Wellcome Trust [to 24 March 2018]
News / Published: 22 March 2018
First Japanese company joins CARB-X partnership
As pharmaceutical company Shionogi becomes the first Japanese company to join CARB-X, Tim Jinks, head of Wellcome’s Drug-Resistant Infections Priority Programme, gives an update on the partnership’s work to develop new drugs and diagnostics.
Last March, Wellcome announced it was committing up to $155 million dollars to CARB-X. CARB-X, which stands for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, now has 28 promising projects in its portfolio. Eight are focusing on new class antibiotics.
These advances mean CARB-X has the world’s largest and most technically diverse portfolio of early development projects to tackle the rapidly increasing global problem of drug-resistant infections…
The Wistar Institute [to 24 March 2018]
Press Release Mar. 23, 2018
Wistar and YourEncore Unite to Advance Life Sciences Opportunities
YourEncore will provide targeted support to Wistar and its international life sciences partners
PHILADELPHIA – (March 23, 2018) -The Wistar Institute and YourEncore, Inc., a life sciences and consumer goods consulting company engaging highly experienced, top talent industry experts, have signed a Memorandum of Understanding (MoU) to help accelerate the advancement of Wistar’s early-stage discoveries, start-ups and international collaborations.
Under the Memorandum, YourEncore and Wistar will be working together to develop a tailored, flexible model that deploys YourEncore’s team of pharmaceutical, biotech and regulatory experts around Wistar’s leading therapeutic and diagnostic programs. YourEncore will also be assisting Wistar’s international partners such as bioXclusters plus, an enterprise of European life sciences companies, on individual projects aimed at strengthening international business relations between the Philadelphia research and biotechnology community and its European life sciences cluster…
Press Release Mar. 19, 2018
The Campbell Foundation Awards $100,000 Grant to The Wistar Institute
nonprofit organization, which is dedicated to funding HIV/AIDS research, has awarded the grant to Mohamed Abdel-Mohsen, Ph.D., assistant professor in Wistar’s Vaccine & Immunotherapy Center.
DCVMN – Developing Country Vaccine Manufacturers Network [to 24 March 2018]
5 April 2018
Webinar: The new Future Vaccine Manufacturing Hub, collaborating with DCVMN
Prof Robin Shattock, Professor of Mucosal Infection and Immunity, Imperial College, London
Thursday, April 5, 2018 9:00 am
Europe Summer Time (Paris, GMT+02:00)